Pacira BioSciences (PCRX) Cash from Investing Activities (2010 - 2026)

Pacira BioSciences' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 175.86% year-over-year to $19.4 million in Q1 2026; TTM through Mar 2026 was $144.6 million, a 254.81% increase from a year earlier, with the FY2025 full-year figure at $99.5 million, up 219.46% from the prior year.
• Cash from Investing Activities climbed to $19.4 million in Q1 2026 per PCRX's latest filing, from $19.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $66.2 million in Q1 2023 and bottomed at -$208.0 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $7.3 million (2023), against an average of -$6.6 million.
• Across the five-year window, Cash from Investing Activities tumbled 1101.36% in 2024 and soared 5353.53% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $11.2 million in 2022, then declined by 25.16% to $8.4 million in 2023, then sank by 104.39% to -$368000.0 in 2024, then surged by 5353.53% to $19.3 million in 2025, then grew by 0.56% to $19.4 million in 2026.
• Per Business Quant, the three latest PCRX Cash from Investing Activities figures stand at $19.4 million (Q1 2026), $19.3 million (Q4 2025), and $43.6 million (Q3 2025).